Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACCLAIM-Lp(a): Lepodisiran for Prevention of Major Adverse Cardiovascular Events
jRCT2051230205Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2024
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic disease and lipoprotein(a) hyperlipoproteinemia (Lp(a)) comparing Lepodisiran sodium with Placebo (2 arms). Primary endpoint: Time to first MACE-4 event. Started Mar 2024; status: active, not recruiting.
02
Drugs
lepodisiran
03
Conditions
atherosclerotic diseaselipoprotein(a) hyperlipoproteinemia (Lp(a))
Beyond the preview
Go deeper on jRCT2051230205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051230205.